Erik de Clercq
Direttore/Membro del Consiglio presso FermaVir Pharmaceuticals LLC
Posizioni attive di Erik de Clercq
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
FermaVir Pharmaceuticals LLC
 FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Direttore/Membro del Consiglio | 16/08/2005 | - |
Storia della carriera di Erik de Clercq
Statistiche
Distribuzione geografica
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 1 |
Settori
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Health Technology |
- Borsa valori
- Insiders
- Erik de Clercq
- Esperienza
